# Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

> **NCT01767194** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 73 (actual)

## Conditions studied

- Ganglioneuroblastoma
- Recurrent Neuroblastoma

## Interventions

- **BIOLOGICAL:** Dinutuximab
- **DRUG:** Irinotecan Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Sargramostim
- **DRUG:** Temozolomide
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01767194
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-12
- **Primary completion:** 2018-06-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2022-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01767194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01767194, "Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01767194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*